TY - JOUR T1 - The endocannabinoid system and the treatment of mood and anxiety disorders. AU - Hill,Matthew N, AU - Gorzalka,Boris B, PY - 2009/06/24/received PY - 2009/07/31/accepted PY - 2009/10/21/entrez PY - 2009/10/21/pubmed PY - 2010/2/13/medline SP - 451 EP - 8 JF - CNS & neurological disorders drug targets JO - CNS Neurol Disord Drug Targets VL - 8 IS - 6 N2 - The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioral responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioral responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders. SN - 1996-3181 UR - https://www.unboundmedicine.com/medline/citation/19839936/The_endocannabinoid_system_and_the_treatment_of_mood_and_anxiety_disorders_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1871-5273&volume=8&issue=6&spage=451&aulast=Hill DB - PRIME DP - Unbound Medicine ER -